Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX013 · 1 trial · 4 indications
Cytokine release syndrome (CRS) assessed according to ASTCT criteria.
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Participants receive JANX013 in combination with JANX007 administered at increasing dose levels per cohort |
| Dose Expansion | EXPERIMENTAL | Participants receive JANX013 in combination with JANX007. Participants will be dosed at levels previously declared tolerable. |
| Name | Type | Description |
|---|---|---|
| JANX013 | DRUG | JANX013 will be administered via IV dosing. |
| JANX007 | DRUG | JANX007 will be administered via IV dosing. |
Key Inclusion Criteria: * Male participants ≥ 18 years of age at the time of signing informed consent * Histologically or cytologically confirmed adenocarcinoma of the prostate For Dose Escalation: \- Have received at least 1 novel ARPI (e.g., abiraterone acetate, enzalutamide, apalutamide, or da...
Top 20 of 55 competitors
JANX013 is an investigational small molecule developed by Janux Therapeutics, Inc. (ticker JANX) for the treatment of prostate cancer. It is being studied in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC), where it is evaluated in combination with another agent, JANX007.
JANX013 is being developed for prostate cancer, specifically for patients with castration-resistant prostate cancer (CRPC), metastatic prostate cancer, and metastatic castration-resistant prostate cancer (mCRPC). It is an investigational therapy and is not yet approved for commercial use; it is currently being evaluated in an early-stage clinical trial.
JANX013 targets PSMA, or prostate-specific membrane antigen, which is an antigen expressed on prostate cancer cells. By binding PSMA, the small molecule is designed to act on prostate cancer cells that carry this target, and it is being studied in patients with metastatic castration-resistant prostate cancer.
JANX013 is being developed by Janux Therapeutics, Inc., a biopharmaceutical company that trades under the ticker symbol JANX. Janux Therapeutics is the sponsor of the Phase 1 clinical trial evaluating JANX013 in combination with JANX007 in patients with metastatic castration-resistant prostate cancer.
JANX013 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The single Phase 1 trial is currently recruiting participants and is designed to enroll approximately 110 patients with prostate cancer, including metastatic castration-resistant prostate cancer.
JANX013 is being studied in one Phase 1 clinical trial, NCT07813637, titled a Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC. The trial is recruiting in the United States, is controlled, is not randomized or double-blind, and plans to enroll 110 male participants aged 18 years and older.